Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30 lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT. Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs. #CancerResearch #Immunotherapy #NKcells @MDAndersonNews

This will be an amazing symposium for those interested in myeloid malignancies. Checkout the exciting program organized by @CollaSimona ! I will be presenting some of our work on NK cell epigenetic scarring in MDS and AML. @MDAndersonNews #MDS #AML #NK

Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases @MDAndersonNews #CellTherapy #endcancer

Excited to share our new publication in @ScienceTM. Incredibly proud of my AML buddy @may_daher for shaping this project. Thanks a ton to our amazing mentor @lab_rezvani for her never ending support and guidance that has been a pivotal part of my professional journey.

Excited to share our manuscript published in @ScienceTM, where we describe a novel NK immune evasion strategy in AML. We found that #BATF is a key transcription factor driving epigenetic reprogramming in NK cells in AML. This TF is induced by the canonical TGF-β/SMAD pathway and leads to persistent NK cell dysfunction. This dysfunction can be prevented by deleting BATF or TGFBR2 upstream, but once established, it cannot be reversed. Designed to overcome epigenetic scarring, we look forward to bringing this novel CAR-NK cell approach to the clinic to improve outcomes for AML patients. @mdandersonnews @lab_rezvani @bijender2050 #AML #NK #CRISPR #epigenetics #BATF

The future of cell therapy! CAR NK! @MDAndersonNews

Tour de force presentation today by Dr. Katy Rezvani @lab_rezvani at the Allison Institute @MDAndersonNews encompassing great science and a proliferative pipeline of cell therapies for our patients with heme and solid cancers! #NK #celltherapy

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents dlvr.it/T393jD

Our Dr. Katy Rezvani, recipient of @ASH_hematology’s 2023 Honorific Award, delivers the E. Donnall Thomas Lecture at #ASH23 on Natural Killer Cells: A New Frontier for Cancer Immunotherapy. We’re grateful for her pioneering contributions to this innovative field and her commitment to #EndCancer. @lab_rezvani

Thank you very much Dr. Brodsky @DocsDock200 for your very kind words! It was such an honor to receive this award from ASH. Please accept my sincere congratulations for presiding over such an amazing #ASH23 @MDAndersonNews

Stunning and brilliant! A stellar lecture by @lab_rezvani to showcase the groundbreaking research and very promising clinical responses in patients treated with #CARNK cells. Katy -may your star keep shining as we carry on our mission to make cancer history @MDAndersonNews #ASH

In an #ASH23 Scientific Spotlight Session, our Dr. May Daher shares insights on metabolic targets and strategies to enhance the efficacy of cellular therapies, such as CAR NK. @ASH_hematology @may_daher #EndCancer

‘The mind is not a vessel to be filled, but a fire to be kindled.’ - Plutarch. Medical training, especially at esteemed institutions like AIIMS, is about igniting this fire, focusing on practical skills and immersive learning, rather than just traditional grading. The hours listed represent a journey of hands-on dedication and in-depth understanding, crucial for the medical profession. @SeeFisch; You must visit to see the magic of @aiims_newdelhi :)

“I work within a field that could potentially result in a cure for at least a subset of patients with cancer,” says our Dr. Katy Rezvani of cellular therapy. Learn how working at MD Anderson has shaped Rezvani’s career and her research: bit.ly/3LOUxtF @GoHealio @lab_rezvani #EndCancer

An amazing presentation by @may_daher at this afternoon’s @SNI_NKMeeting session on her research in the impact of AML on NK cells. So very proud of all that she is doing to give hope to our patients #NK #NKCAR #NK2023 ⁦@MDAndersonNews⁩

Wonderful to celebrate such impressive scientific progress @EBMT2023 @lab_rezvani #NKcells for CAR therapy 👏👏 So many more exciting Rx options for our patients since our training together #HammersmithHospital ‘some years’ ago with fabulous John Goldman @charliecraddock

Awe-inspiring talk by Dr. Katy Rezvani ⁦@lab_rezvani⁩ ⁦@MDAndersonNews⁩ #EBMT2023! Impressive pipeline of NK cell based immunotherapies for multiple heme and solid cancers!! And this incredible response👇🏻 with CD70- directed CAR-NK cells!!! The future is bright!! 🤩

When your mentor is a celebrity 😎 @lab_rezvani

@lab_rezvani @MDAndersonNews gives a masterclass in #NK Immunotherapy #SITC22. A must for all. @sitcancer 2022.sitc.showcare.io/lesson…

Very excited to show this video that depicts macrophage - stem cell interactions. Someday, we hope to alter this interaction to remove pre malignant or leukemic clones of stem cells.